Response to Clenbuterol in Humans

Last updated: August 8, 2024
Sponsor: University of Copenhagen
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Placebo

Clenbuterol Oral Product

Clinical Study ID

NCT03860870
CLEN
  • Ages 18-40
  • Male
  • Accepts Healthy Volunteers

Study Summary

Due to the long half-life (~36 hr) of clenbuterol, detection methods such as dried blood spots (DBS) are a potentially suitable method to easily and non-invasively detect doping misuse of this compound for several days after ingestion. If, and how long, the compound can be detected by DBS has not yet been investigated but is of interest due to its potential in doping-control. The aim is to evaluate whether abuse of clenbuterol can be detected at relevant concentration levels in samples obtained using DBS and to assess the physiological response to clenbuterol in skeletal muscle..

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy

  • Male

  • 18-40 years of age

  • No known contraindications for anabolic drugs (e.g. cancer)

Exclusion

Exclusion Criteria:

  • Abnormal ECG

  • Steroid abuse

  • Ongoing use of prescription medication

  • heavy resistance training more than 2 times weekly

  • Disease deemed by the MD to infer a risk to participate in the trial

Study Design

Total Participants: 16
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
March 11, 2019
Estimated Completion Date:
December 21, 2022

Connect with a study center

  • August Krogh Building

    Copenhagen,
    Denmark

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.